玉屏风颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘临床研究

Clinical Study on Yupingfeng Granules Combined with Budesonide and Formoterol Fumarate Powder for Inhalation for the Treatment of Bronchial Asthma

目的:观察玉屏风颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效及对患者症状控制、肺功能、血清学指标的影响。方法:将支气管哮喘患者92例纳入研究,采用随机数字表法分为对照组与试验组各46例。对照组予以布地奈德福莫特罗粉吸入剂治疗,试验组在对照组基础上加用玉屏风颗粒治疗。治疗后,比较2组临床疗效及不良反应发生率,以及治疗前后症状控制[症状评分、哮喘控制测试(ACT)评分]、肺功能指标[第1秒用力呼气容积(FEV_(1))、最大呼气流量(PEF)、呼吸频率]及血清学指标[血管内皮生长因子(VEGF)、S100钙离子结合蛋白A4(S100A4)、嗜酸性阳离子蛋白(ECP)]水平。结果:治疗后,试验组总有效率为97.83%,高于对照组80.43%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组咳喘、咳痰、胸闷、哮鸣音等症状评分均较治疗前降低(P<0.05),且试验组上述各项评分均低于对照组(P<0.05)。治疗后,2组ACT评分较治疗前升高(P<0.05),且试验组ACT评分高于对照组(P<0.05)。治疗后,2组FEV_(1)、PEF水平较治疗前升高(P<0.05),呼吸频率较治疗前降低(P<0.05);且试验组FEV_(1)、PEF水平高于对照组(P<0.05),呼吸频率低于对照组(P<0.05)。治疗后,2组血清VEGF、S100A4、ECP水平均较治疗前降低(P<0.05),且试验组上述3项指标均低于对照组(P<0.05)。治疗期间,试验组不良反应发生率为10.87%,对照组为6.52%,2组比较,差异无统计学意义(P>0.05)。结论:玉屏风颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘疗效确切,可有效控制患者临床症状,改善肺功能,其机制可能与下调血清VEGF、S100A4、ECP水平有关。

Objective:To observe the clinical effect of the therapy of Yupingfeng Granules combined with Budesonide and Formoterol Fumarate Powder for Inhalation on bronchial asthma and its effects on the symptom control,lung function and orrhology indexes of patients.Methods:A total of 92 patients with bronchial asthma were included into the study and divided into the control group and the trial group according to the random number table method,with 46 cases in each group.The control group was given Budesonide and Formoterol Fumarate Powder for Inhalation for treatment,and the trial group was additionally treated with Yupingfeng Granules based on the treatment of the control group.After treatment,the clinical effects,incidence of adverse reactions,symptoms control[syndrome scores and scores of Asthma Control Test(ACT)],and the levels of lung function indexes[forced expiratory volume in one second(FEV_(1)),peak expiratory flow(PEF)and breathing rate]and of orrhology indexes[vascular endothelial growth factor(VEGF),S100 calcium binding protein A4(S100A4)and eosinophil cationic protein(ECP)]were compared before and after treatment between the two groups.Results:After treatment,the total effective rate was 97.83%in the trial group,higher than that of 80.43%in the control group,the difference being significant(P<0.05).After treatment,the syndrome scores of cough and gasp,expectoration,suppression in the chest,and wheezing rale in the two groups were decreased when compared with those before treatment(P<0.05),and the above four scores in the trial group were lower than those in the control group(P<0.05).After treatment,the ACT scores in the two groups were increased when compared with those before treatment(P<0.05),and the ACT score in the trial group was higher than that in the control group(P<0.05).After treatment,the levels of FEV_(1) and PEF in the two groups were increased when compared with those before treatment(P<0.05),and the breathing rate was decreased when compared with that before treatment(P<0.05);the levels of FEV_(1) and PEF in the trial group were higher than those in the control group(P<0.05),and the breathing rate was lower than that in the control group(P<0.05).After treatment,the levels of serum VEGF,S100A4 and ECP in the two groups were decreased when compared with those before treatment(P<0.05),and the above three levels in the trial group were lower than those in the control group(P<0.05).During treatment,the incidence of adverse reactions was 10.87%in the trial group and 6.52%in the control group,there being no significance in the difference(P>0.05).Conclusion:The therapy of Yupingfeng Granules combined with Budesonide and Formoterol Fumarate Powder for Inhalation has a definite curative effect on bronchial asthma,which can effectively control the clinical symptoms and improve the lung function,and its mechanism may be related to the down-regulation of levels of serum VEGF,S100A4 and ECP.